EBSEmergent BioSolutions Inc.
Price
-31%1YEnd-of-day closes, not the intraday tick.
Mostly good, one thing to check: safety
Quality strong, a flag to check, undemanding price, the market undecided.
Charts
As reported to the SEC, without any scoring.
Emergent BioSolutions Inc. (EBS) reported revenue of $234M in Q2 2026 (quarter ended Jun 30, 2026), up 66% from the same quarter a year earlier. That came with a gross margin of 59% and net loss of $180M. For the full year FY2025, revenue was $743M (−29% year on year) and net income $53M. The next results filing is expected around Oct 28, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 1, 2026On August 18, 2026, Emergent BioSolutions Inc. (“Emergent”) received a contract modification (“Modification No. 21”) of the BARDA AV7909 Contract (as defined below) from the Office of the Assistant Secretary for Preparedness and Response to procure additional doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted) …Other event · Form 8-K
- Aug 5, 2026On August 5, 2026, the Company announced an organizational restructuring plan (the “Restructuring Plan”) intended to strengthen its long-term financial position in response to changes in its business.Earnings release · Form 8-K
- Jun 29, 2026On June 26, 2026, Emergent BioSolutions Inc. (the “Company,” including its wholly-owned subsidiaries, “Emergent”), through its wholly-owned subsidiary, Emergent Product Development Gaithersburg Inc., received a contract modification from the Office of the Assistant Secretary for Preparedness and Response (“ASPR”), an …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, Specialty & Generic
Ranks #31 of 41 by RyuScore